2026 BIO Asia TAIWAN

Pythia Biotech Successfully Concludes Its Participation at BIO Asia–Taiwan 2026, Showcasing Innovations in Its Tumor Microenvironment-on-a-Chip Platform

Pythia Biotech successfully concluded its four-day exhibition at BIO Asia–Taiwan 2026, where the company showcased its proprietary Tumor Microenvironment-on-a-Chip (TME-Chip) platform and Microphysiological System (MPS) technology. During the exhibition, Pythia introduced the platform's core technologies and demonstrated its applications in cancer research, drug discovery, translational medicine, and precision oncology to biotechnology, pharmaceutical, healthcare, and academic professionals from around the world.

Throughout the event, the Pythia team engaged in productive discussions with research institutions, biotechnology and pharmaceutical companies, healthcare professionals, and industry partners from both Taiwan and overseas. The team shared the latest progress and application outcomes of the TME-Chip platform while exploring potential collaborations in tumor modeling, therapeutic efficacy evaluation, immuno-oncology, drug penetration studies, and treatment response prediction.

Participation in BIO Asia–Taiwan 2026 further strengthened Pythia Biotech's relationships with existing collaborators while establishing new connections with prospective customers and international partners. These interactions expanded the company's collaborative network across the Asia-Pacific region and global markets, further enhancing Pythia's international visibility in the fields of tumor microenvironment modeling and microphysiological systems.

During the four-day exhibition, Dr. Kien-Thiam Tan, Chief Executive Officer of Pythia Biotech, delivered two featured stage presentations highlighting the company's core technologies, the unique advantages of the TME-Chip platform, and its long-term vision. He also shared how human-relevant tumor microenvironment models can advance cancer research, drug development, and precision treatment decision-making. The presentations attracted strong interest from professionals across academia, industry, and the healthcare sector, generating active discussions and receiving highly positive feedback.



Pythia Biotech sincerely thanks all visitors, collaborators, and industry partners who visited the company's booth and shared valuable insights throughout the exhibition. Looking ahead, the company remains committed to advancing the validation, commercialization, and broader application of the TME-Chip platform. By providing robust, scalable, and human-relevant tumor models, Pythia aims to accelerate oncology drug development and facilitate the translation of precision medicine into clinical practice.